Trial · NCT05726916
Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome
NCT05726916, Phase 3, Recruiting, Assistance Publique - Hôpitaux de Paris
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome. Trials, record NCT05726916. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05726916
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Eculizumab in Hypertensive Emergency-associated Hemolytic Uremic Syndrome
- NCT number
- NCT05726916
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 66 participants, estimated
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Conditions
- Hypertensive Emergency-associated Hemolytic Uremic Syndrome
- Interventions
- Soliris®, Renin angiotensin system blockers
- First posted
- 2023-02-14
- Last updated
- 2024-01-05
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | 6-month response to therapy | 6 month | 6-month response to therapy, as defined by the absence of any of the following events: i) lack of renal efficacy at 6-month follow-up: persistent renal replacement therapy, eGFR \<15ml/mn/1,73m2, or patient death; ii) lack of early hemolysis control with persistent hemolysis at W2 despite well conducted antihypertensive therapy. Any Eculizumab rescue in the control group will be considered as a failure. |
| Secondary | Frequency of Complement genetic rare variants | up to 12 months | |
| Secondary | Rate of renal replacement therapy | Week 13 and 12 months | Evaluation of renal replacement therapy need at Week 13 and months 12 |
| Secondary | Frequency of severe infections | up to 12 months | defined by the need for hospitalization |
| Secondary | Time to resolution of hemolysis | up to 12 months | Evaluation of hemolysis markers (anamia, thrombocytopenia, low hatoglobin, elevated lacticodehydrogenase, schistocytes) |
| Secondary | Frequency of kidney lesions | up to 12 months | |
| Secondary | Costs relating to renal replacement therapy (or lack of) | up to 12 months | |
| Secondary | Costs relating to Eculizumab therapy | up to 12 months | |
| Secondary | Costs relating to other antihypertensive treatments | up to 12 months | |
| Secondary | Costs relating to hospitalizations | up to 12 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05726916
GET https://conductscience.org/api/trials/v1/NCT05726916/registered